The polyphenolic phytoalexin polydatin inhibits amyloid aggregation of recombinant human prion protein. Issue 42 (28th July 2021)

• Record Type: Journal Article
• Authors: Sirohi, Preeti Rana; Kumari, Anchala; Admane, Nikita; Somvanshi, Pallavi; Grover, Abhinav
• Is Part Of: RSC advances. Volume 11:Issue 42(2021)
• Page Start: 25901
• Page End: 25911
• Publication Date: 2021-07-28
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1ra01891d
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : Polydatin is found to be a pharmacologically-significant scaffold that can bind to the rPrP res repertoire and inhibit its conversion to the highly infectious and neurotoxic PrP Sc -like form, thus acting like a promising anti-prion drug lead. Abstract : Prion diseases involve misfolded and highly infectious aggregates of prion protein (PrP Sc ) which forms amyloid plaques leading to fatal neurodegeneration. The absence of clinically proven therapeutics makes the discovery of effective remedial interventions a prime concern. Herein, we report novel prion intervention by the polyphenolic phytoalexin, polydatin which binds with moderate affinity to the recombinant protease resistant core of human prion protein, encompassing the sequence 90–231 (rPrP res ) and inhibits its conversion into the highly neurotoxic forms. An extensive evaluation using biophysical techniques revealed that polydatin incubated rPrP res samples generate off-pathway oligomers having reduced cross-β sheet signature, and relatively smaller in size than the native rPrP res oligomers. The detailed structural analysis using molecular dynamics simulations elucidated the induction of antagonistic mobilities in the β2–α2 loop, α3 helix and the N-terminal amyloidogenic region of prions. This study puts forward novel prion fibrillogenesis inhibitory potential of polydatin, specifically by stabilizing the N-terminal amyloidogenic region. Collectively our results affirm the importance of polydatin in crippling the prion pathogenesis and may serve as a structural scaffold for designing novel therapeutic agents targeting amyloidogenic transition in prions.